Evidence map›Paper›PMID 42573703›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

SsrA-Based Targeted Protein Degradation in Escherichia coli.

Qichang Nie, Terrence Chi-Kong Lau

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Qichang NieDepartment of Biomedical Sciences, College of Biomedicine, City University of Hong Kong, Kowloon, Hong Kong, SAR, China.
Terrence Chi-Kong LauDepartment of Biomedical Sciences, College of Biomedicine, City University of Hong Kong, Kowloon, Hong Kong, SAR, China. chiklau@cityu.edu.hk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted protein degradation is an emerging concept of drug discovery to selectively eliminate the pathogenic proteins by activating their degradation in cells. The proteolysis-targeting chimeras (PROTACs) are bifunctional small molecules that induce the degradation of a protein of interest (POI) by proteasome. Here we describe a method that utilizes an ssrA-based BacPROTAC (bacterial PROTACs) to target the drug-resistant proteins CTX-M-14, a class A β-lactamase commonly found in extended-spectrum beta-lactamase (ESBL) plasmids of antimicrobial resistance (AMR) bacteria. This strategy could resensitize the drug-resistant bacteria and revive previously disregarded antibiotics, opens up a new avenue for therapeutic development of AMR bacteria.

Indexed as

Escherichia coliEscherichia coli ProteinsProteolysisbeta-LactamasesPlasmidsProteasome Endopeptidase ComplexProteolysis Targeting Chimerabeta-LactamasesEscherichia coli ProteinsProteasome Endopeptidase ComplexProteolysis Targeting ChimeraAntimicrobial resistanceBacPROTACsESBL plasmidsEscherichia coliProteasomeProtein degradation

Identifiers

PMID42573703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.